Phase 2 Type 2 Diabetes Trial, Recruiting NCT03899883 Sponsor: University of Colorado, Denver Condition: Type 2 Diabetes
Back to Type 2 Diabetes

Phase 2 Type 2 Diabetes Trial, Recruiting

NCT03899883
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are male
  • People between 18 and 25 years old
  • People diagnosed with type 2 diabetes before the age of 21
  • People with a uric acid level of 5 mg/dl or higher (as measured by a blood test)

Who may not be able to join:

  • People with a condition called Glucose-6-phosphate (G6P) deficiency
  • People with allergies to seafood or iodine
  • People who are unable to have an MRI scan, including those with severe claustrophobia, certain implanted medical devices that are not safe for MRI, or who weigh 450 pounds or more
  • People whose HbA1c (a measure of long-term blood sugar levels) is 12% or higher
  • People who were diagnosed with diabetic ketoacidosis (DKA) or a severe high blood sugar episode within the past month
  • People with congestive heart failure (a condition where the heart does not pump blood effectively)
  • People with a history of multiple or severe allergic reactions, including life-threatening allergic reactions (anaphylaxis)
  • People currently taking medications that lower uric acid levels, such as allopurinol or febuxostat
  • People currently taking certain specific medications, including pegvisomant, pegvaliase, peginterferon alfa 2b, peginterferon alfa 2a, pegfilgrastim, pegaspargase, pegaptanib, pegademase, or certolizumab pegol (confirm with trial site if unsure about any medications)
  • People who have taken part in another clinical research study within the 2 weeks before joining this trial

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 9 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: 720-777-2560

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Registry
ClinicalTrials.gov
Start date
1 January 2020
Est. completion
30 June 2023

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Cardiovascular Markers; Pulse Wave Velocity (PWV); Wall Shear Stress (WSS); Renal Blood Flow; Glomerular Filtration Rate; Albumin Excretion Rate (AER)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 9 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov